← Back to Search

Prescription Digital Therapeutic

Single arm for Schizophrenia

N/A
Waitlist Available
Research Sponsored by Click Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from week 3 to week 7 of the mobile agnew relationships measure
Awards & highlights
No Placebo-Only Group

Summary

This trial tests CT-155, a software-based treatment for adults with schizophrenia. The software offers activities and exercises to help manage symptoms.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week 3 to week 7 of the mobile agnew relationships measure
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from week 3 to week 7 of the mobile agnew relationships measure for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility and acceptability with the study app as measured by Mobile App Rating Scale (MARS) at week 7
Secondary study objectives
Change in strength of digital working alliance from Week 3 to Week 7 as assessed by the Mobile Agnew Relationships Measure (mARM)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single armExperimental Treatment1 Intervention
Single arm acceptability and feasibility of CT-155.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CT-155 smartphone app
2022
N/A
~50

Find a Location

Who is running the clinical trial?

Click Therapeutics, Inc.Lead Sponsor
16 Previous Clinical Trials
2,989 Total Patients Enrolled
5 Trials studying Schizophrenia
807 Patients Enrolled for Schizophrenia
Shaheen Lakhan, MDPhD, FAANStudy ChairClick Therapeutics
4 Previous Clinical Trials
286 Total Patients Enrolled
1 Trials studying Schizophrenia
48 Patients Enrolled for Schizophrenia
~15 spots leftby Oct 2025